Benzinga | Aug 12, 2021 05:19PM EDT

Sight Sciences Q2 Sales $12.5M, Up 258% YoY

* Generated second quarter 2021 total revenue of $12.5 million, an increase of 258% compared to the prior year period, including; Surgical Glaucoma sales of $12.0 million, an increase of 263% compared to the prior year period Dry Eye sales of $0.5 million, an increase of 169% compared to the prior year period

* Expanded gross margin to 82% in the second quarter 2021 versus 40% in the prior year period

* Completed an initial public offering in July raising approximately $253 million of net proceeds after deducting underwriting discounts and commissions and estimated offering expenses